Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

August 6, 2026

Company name: TAUNS Laboratories, Inc.
Representative: Masaki Nonaka, President and CEO
(Code no.: 197A, Standard Market, Tokyo Stock Exchange)
Contact person: Yoshio Uchiyama, Director and CFO
Tel: +81-55-953-9590

Notice of Participation in the ASAGI Labs Longevity Consortium

TAUNS Laboratories, Inc. (headquartered in Izunokuni-shi, Shizuoka, Japan; Masaki Nonaka, President and CEO; Securities Code: 197A; hereinafter "the Company") hereby announces that it has joined the ASAGI Labs Longevity Consortium, organized by the ASAGI Labs Foundation (Chair: Motoshi Hayano, Ph.D).

1. Background and Purpose of Participation

The ASAGI Labs Longevity Consortium aims to achieve both individual life design based on personal narratives and the well-being of society as a whole, against the backdrop of advances in aging research, the integration of multimodal information through AI, and the emergence of multi-stage life models.

As a co-creation platform bringing together academia, corporations, local governments, healthcare institutions, and non-profit organizations, the Consortium promotes the development of Japan-originated longevity solutions for the global market. It advances research, development, and new business creation based on three core principles:

Longevity: Extending healthy life expectancy and enabling sustainable social participation

Narrative: Designing life paths based on each individual's personal story

Multi-stage Life: Transitioning from the traditional model of education, employment, and retirement to a multi-stage approach to life

In its Med-Term Management Plan, the Company has established the vision of "Solving social issues with diagnostic technology, data, and AI." While healthcare demand continues to grow as the population ages, healthcare resources remain limited. To address this social challenge, the Company aims to build a framework that continuously creates next-generation testing technologies supporting diagnostic workflows by combining diagnostic technologies with data and AI, thereby contributing to the optimization of diagnostic processes across society.

The expansion of the Company's testing platform and the development of its data and AI infrastructure have the potential to serve as a foundation supporting the new social model envisioned by the Consortium and to contribute to the realization of longevity. Furthermore, the Consortium's research, development, and co-creation activities are highly aligned with the initiatives outlined in the Company's Med-Term Management Plan, creating opportunities for diverse collaborations.

Through participation in the Consortium and collaboration with academia, corporations, local governments, healthcare institutions, and non-profit organizations, the Company will contribute to research, development, and new business creation aimed at realizing longevity, while further accelerating its business strategy. Through the realization of its corporate slogan, "Peace of mind through diagnostic technology," the Company will contribute to building a sustainable and prosperous society.

2. Overview of the ASAGI Labs Longevity Consortium

(1) Name	ASAGI Labs Longevity Consortium
(2) Secretariat	ASAGI Labs Foundation
(3) Representative of Secretariat	Motoshi Hayano, Chair
(4) Activities	１． Information exchange and knowledge sharing related to longevity-focused research, development, and business creation. ２． Promotion of joint research and social implementation projects through collaboration among industry, government, and academia in Japan and abroad. ３． Dissemination of information on longevity, public awareness activities, and policy recommendations. ４． Other activities necessary to achieve the objectives of the Consortium.
(5) Date of Establishment	June 1, 2026
(6) Website	https://www.asagiconsortium.com/